4P-Pharma is delighted to welcome Emmanuelle Lopez appointed as a Chief Financial Officer. She has substantial experience and background in both pharma and biotech companies.

Emmanuelle Lopez is joining our company at its best time where we are taking an important turn in our growth with the start of our clinical trials. Together, we are confident in bringing new medicine to patients.


About Emmanuelle Lopez

Emmanuelle Lopez has been our Chief Financial Officer since April 2022. She has more than 25 years’ experience in finance, legal, human resources, and Information Systems.

She has worked for different pharmaceutical & biotech companies (IPSEN, DBV Technologies).

From 2015 to 2021, she was the financial Vice President at DBV Technologies where she led all the financial documentation for the different fundraising of the company on Nasdaq and Euronext Paris (>m700€). She also set up SOXX and created a department dedicated to Risks and its management.

Prior to DBV, she worked at Ipsen for 19 years where she held various roles in the group finance department and participated in the company’s IPO on Euronext.

She received a master’s degree in Management (Finance & Tax) from University Paris IX Dauphine and has obtained the ARM 54 certificate – Risk Management Principles & Practices from the institutes (Risk & insurance Knowledge Group).